Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. (Q38961789)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

review article

1 reference

title

Altered metabolite levels in cancer: implications for tumour biology and cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

author name string

Dan Y Gui

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Matthew G Vander Heiden

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

language of work or name

English

0 references

publication date

23 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

page(s)

680-693

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27658530%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2016.85

23 March 2020

exact match

0 references

cites work

Heterogeneity of tumor-induced gene expression changes in the human metabolic network

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The Warburg Effect: How Does it Benefit Cancer Cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The Emerging Hallmarks of Cancer Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

MYC, Metabolism, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Targeting metabolic transformation for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Targeting cancer metabolism: a therapeutic window opens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitochondrial tumour suppressors: a genetic and biochemical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The pathophysiology and treatment of hereditary tyrosinemia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

21 January 2018

Mitochondria and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

21 January 2018

SDH mutations in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Targeting glucose metabolism for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Causes and consequences of increased glucose metabolism of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pyruvate kinase M2 is a phosphotyrosine-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Serine is a natural ligand and allosteric activator of pyruvate kinase M2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pyruvate kinase type M2 and its role in tumor growth and spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Small Molecule Activation of PKM2 in Cancer Cells Induces Serine Auxotrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Expanding chemical biology of 2-oxoglutarate oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Induction of sarcomas by mutant IDH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Insulator dysfunction and oncogene activation in IDH mutant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Hypoxia Induces Production of L-2-Hydroxyglutarate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

SDH mutations establish a hypermethylator phenotype in paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome"

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Cell transformation by the superoxide-generating oxidase Mox1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitochondrial reactive oxygen species and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Proteomic detection of hydrogen peroxide-sensitive thiol proteins in Jurkat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

A proton relay enhances H2O2 sensitivity of GAPDH to facilitate metabolic adaptation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Reversible inactivation of the tumor suppressor PTEN by H2O2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Oxidative Dimerization of PHD2 is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1α Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

JunD reduces tumor angiogenesis by protecting cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Dicarbonyl proteome and genome damage in metabolic and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The glyoxalase pathway: the first hundred years... and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

GLO1-A novel amplified gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Functional lysine modification by an intrinsically reactive primary glycolytic metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Fumarate induces redox-dependent senescence by modifying glutathione metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Alkylation and inactivation of human glutathione transferase zeta (hGSTZ1-1) by maleylacetone and fumarylacetone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

On the enzymic defects in hereditary tyrosinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The occurrence of hepatoma in the chronic form of hereditary tyrosinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Glutathione dependent metabolism and detoxification of 4-hydroxy-2-nonenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Mitochondrial reactive oxygen species regulate hypoxic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Induction of the mitochondrial NDUFA4L2 protein by HIF-1α decreases oxygen consumption by inhibiting Complex I activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

NRF2 and cancer: the good, the bad and the importance of context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

The emerging role of the Nrf2-Keap1 signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Antioxidants accelerate lung cancer progression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Pathological effects of glyoxalase I inhibition in SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

RETRACTED: Selective killing of cancer cells by a small molecule targeting the stress response to ROS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Regulation of ferroptotic cancer cell death by GPX4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Oxidative stress inhibits distant metastasis by human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Antioxidants can increase melanoma metastasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Reductive carboxylation supports growth in tumour cells with defective mitochondria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Molecular changes associated with chronic liver damage and neoplastic lesions in a murine model of hereditary tyrosinemia type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.85

Production of large amounts of hydrogen peroxide by human tumor cells

31 March 2020

1 reference

12 December 2020

Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin

1 reference

12 December 2020

An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma

1 reference

12 December 2020

Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma

1 reference

12 December 2020

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

1 reference

12 December 2020

Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells

1 reference

12 December 2020

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.

1 reference

12 December 2020

Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.

1 reference

12 December 2020